From: The market trend analysis and prospects of cancer molecular diagnostics kits
Category / Year | 2013 | 2014 | 2015 | 2016 | 2017 | 2018 | 2019 | CAGR | |
---|---|---|---|---|---|---|---|---|---|
RT-PCR | Leukemia | 35.7 | 37.6 | 47.6 | 60.3 | 76.4 | 96.7 | 122.5 | 26.6% |
Lymphoma | 5.8 | 6.8 | 10.9 | 17.3 | 27.6 | 44.1 | 70.4 | 59.6% | |
Sub-total | 41.5 | 44.4 | 58.5 | 77.6 | 104.0 | 140.8 | 192.9 | 34.1% | |
DNA microarray | Leukemia | 20.8 | 22.0 | 28.8 | 37.7 | 49.3 | 64.5 | 84.4 | 30.9% |
Lymphoma | 10.2 | 11.9 | 20.5 | 35.3 | 60.7 | 104.5 | 179.8 | 72.1% | |
Sub-total | 31.0 | 33.9 | 49.3 | 73.0 | 110.0 | 169.0 | 264.2 | 50.8% | |
LOAC | Leukemia | 3.0 | 3.2 | 4.1 | 5.2 | 6.7 | 8.5 | 10.9 | 27.8% |
Lymphoma | Â | ||||||||
Sub-total | 3.0 | 3.2 | 4.1 | 5.2 | 6.7 | 8.5 | 10.9 | 27.8% | |
NGS | Leukemia | 15.0 | 25.5 | 44.3 | 76.9 | 133.5 | 231.7 | 402.3 | 73.6% |
Lymphoma | 13.8 | 17.8 | 34.2 | 65.9 | 126.8 | 244.0 | 469.4 | 92.4% | |
Sub-total | 28.8 | 43.3 | 78.5 | 142.8 | 260.3 | 475.7 | 871.7 | 82.3% | |
Multiplex conventional | Leukemia | Â | |||||||
Lymphoma | 13.1 | 15.4 | 24.0 | 37.3 | 58.1 | 90.4 | 140.8 | 55.7% | |
Sub-total | 13.1 | 15.4 | 24.0 | 37.3 | 58.1 | 90.4 | 140.8 | 55.7% | |
Blood cancer total | 117.4 | 140.2 | 214.4 | 335.9 | 539.1 | 884.4 | 1480.5 | 60.2% |